Tibotec

Tibotec is a pharmaceutical company with a focus on research and development for the treatment of infectious diseases such as HIV (AIDS), and Hepatitis C. The company develops antiretroviral drugs for the treatment of AIDS.

History

In 1994, Rudi Pauwels (Rega Institute for Medical Research) founded Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels (Janssen Pharmaceutica) joined Tibotec. The company was acquired by Johnson & Johnson in April 2002. The name of the company is derived from the tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium)^[1].

Drugs

• TMC114 (darunavir, tradename Prezista), a protease inhibitor (PI), (recently approved by the FDA)
• TMC125, (etravirine, tradename Intelence) a non-nucleoside reverse transcriptase inhibitor (NNRTI), (recently approved by the FDA)
• TMC207, an experimental diarylquinoline anti-tuberculosis drug^[2]
• TMC278, (rilpivirine) an NNRTI.

Tibotec licensed TMC120, an NNRTI, to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.

See also

• Virco
• Galapagos Genomics
• Janssen Pharmaceutica
• FlandersBio

References

1. ^ Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, et al., Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives, Nature, 1990, 343, 470-474. doi:10.1038/343470a0
2. ^ Andries K, Verhasselt P, Guillemont J, et al. (2005), A diarylquinoline drug active on the ATP-synthase of Mycobacterium tuberculosis, Science 307 (5707): 223–27

External links

• Tibotec

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. v • d • e